Hypotension - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Hypotension - Pipeline Review, H2 2019’, provides an overview of the Hypotension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypotension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypotension

- The report reviews pipeline therapeutics for Hypotension by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hypotension therapeutics and enlists all their major and minor projects

- The report assesses Hypotension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hypotension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypotension

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypotension pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cerecor Inc

Handa Pharmaceuticals LLC

La Jolla Pharmaceutical Company

Theravance Biopharma Inc

TrioxBio Inc

Cerecor Inc

Handa Pharmaceuticals LLC

La Jolla Pharmaceutical Company

Theravance Biopharma Inc

TrioxBio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypotension - Overview

Hypotension - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypotension - Overview

Hypotension - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypotension - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypotension - Companies Involved in Therapeutics Development

Cerecor Inc

Handa Pharmaceuticals LLC

La Jolla Pharmaceutical Company

Theravance Biopharma Inc

TrioxBio Inc

Hypotension - Drug Profiles

ampreloxetine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

angiotensin II acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dopamine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HND-024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTR-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylephrine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rislenemdaz - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypotension - Dormant Projects

Hypotension - Product Development Milestones

Featured News & Press Releases

Jul 22, 2019: Theravance Biopharma reports new data from phase 2 study of ampreloxetine (TD-9855) in oral presentation at 32nd European Neurology Congress

Jun 28, 2019: La Jolla Pharmaceutical Company receives positive CHMP opinion for GIAPREZA (angiotensin II) for the treatment of refractory Hypotension in adults with septic or other distributive shock

Jun 18, 2019: Theravance Biopharma reports new data from phase 2 study of Ampreloxetine (TD-9855) in presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress

Jun 11, 2019: BrePco Biopharma announce the presentation of selected results of late-stage clinical trial in extremely premature neonates

Mar 25, 2019: Theravance Biopharma announces Ampreloxetine (TD-9855) phase 2 study results selected for oral presentation at 32nd European Neurology Congress

Jan 29, 2019: Theravance doses first patient in Phase III trial of ampreloxetine

Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension

May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension

Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018

Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State

Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501

May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hypotension, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by ...

List of Tables

Number of Products under Development for Hypotension, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hypotension - Pipeline by Cerecor Inc, H2 2019

Hypotension - Pipeline by Handa Pharmaceuticals LLC, H2 2019

Hypotension - Pipeline by La Jolla Pharmaceutical Company, H2 2019

Hypotension - Pipeline by Theravance Biopharma Inc, H2 2019

Hypotension - Pipeline by TrioxBio Inc, H2 2019

Hypotension - Dormant Projects, H2 2019

List of Figures

List of Figures

Number of Products under Development for Hypotension, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by ...

List of Figures

Number of Products under Development for Hypotension, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports